Timeline: chemotherapy and the war on cancer
10.1038/nrc1529 · 2005
Management of small cell lung cancer: recent developments for optimal care
10.2165/11597640-000000000-00000 · 2012
Bendamustine: a review of its use in the management of chronic lymphocytic leukaemia, rituximab-refractory indolent non-Hodgkin's lymphoma and multiple myeloma
10.2165/11209510-000000000-00000 · 2012
DNA repair pathways as targets for cancer therapy
10.1038/nrc2342 · 2008
DNA interstrand cross-linking agents and their chemotherapeutic potential
10.2174/092986712803414295 · 2012
The DNA damage response and cancer therapy
10.1038/nature10760 · 2012
The MRE11 complex: starting from the ends
10.1038/nrm3047 · 2011
Harnessing synthetic lethal interactions in anticancer drug discovery
10.1038/nrd3374 · 2011
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism
10.1038/nrg1879 · 2006
PKB/Akt promotes DSB repair in cancer cells through upregulating Mre11 expression following ionizing radiation
10.1038/onc.2010.467 · 2011
Inhibition of phosphatidylinositol-3-OH kinase/Akt signaling impairs DNA repair in glioblastoma cells following ionizing radiation
10.1074/jbc.m703042200 · 2007
Down-regulation of Rad51 expression overcomes drug resistance to gemcitabine in human non-small-cell lung cancer cells
10.1124/jpet.110.173146 · 2010
Targeting of AKT1 enhances radiation toxicity of human tumor cells by inhibiting DNA-PKcs-dependent DNA double-strand break repair
10.1158/1535-7163.mct-07-2200 · 2008
DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation
10.1038/nature01368 · 2003
Distinct functional domains of Nbs1 modulate the timing and magnitude of ATM activation after low doses of ionizing radiation
10.1038/sj.onc.1207447 · 2004
Targeting the phosphoinositide 3-kinase pathway in cancer
10.1038/nrd2926 · 2009
Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises
10.1016/j.coph.2008.08.004 · 2008
Class I PI3 kinase inhibition by the pyridinylfuranopyrimidine inhibitor PI-103 enhances tumor radiosensitivity
10.1158/0008-5472.can-08-0757 · 2008
Drug discovery approaches targeting the PI3K/Akt pathway in cancer
10.1038/onc.2008.246 · 2008
Biochemical characterization of the ataxia-telangiectasia mutated (ATM) protein from human cells
10.1016/j.dnarep.2004.03.041 · 2004
In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002)
2000
Phosphatidylinositol 3-kinase inhibitor(LY294002) induces apoptosis of human nasopharyngeal carcinoma in vitro and in vivo
10.1186/1756-9966-29-34 · 2010
Inhibition of the phosphatidylinositol 3′-kinase-AKT pathway induces apoptosis in pancreatic carcinoma cells in vitro and in vivo
2002
The in vitro and in vivo effects of 2-(4-morpholinyl)-8-phenyl-chromone (LY294002), a specific inhibitor of phosphatidylinositol 3′-kinase, in human colon cancer cells
2002
Disulfiram treatment facilitates phosphoinositide 3-kinase inhibition in human breast cancer cells in vitro and in vivo
10.1158/0008-5472.can-09-3752 · 2010
Inhibition of phosphatidylinositol 3′-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models
2002
Phosphatidylinositol 3-kinase inhibition by LY294002 radiosensitizes human cervical cancer cell lines
10.1158/1078-0432.ccr-05-1084 · 2006
Potent antitumor bifunctional DNA alkylating agents, synthesis and biological activities of 3a-aza-cyclopenta[a]indenes
10.1016/j.bmc.2009.06.018 · 2009
IFN-induced protein with tetratricopeptide repeats 2 inhibits migration activity and increases survival of oral squamous cell carcinoma
10.1158/1541-7786.mcr-08-0141 · 2008
The novel DNA alkylating agent BO-1090 suppresses the growth of human oral cavity cancer in xenografted and orthotopic mouse models
10.1002/ijc.26142 · 2012
Combination of bifunctional alkylating agent and arsenic trioxide synergistically suppresses the growth of drug-resistant tumor cells
10.1593/neo.10110 · 2010
DNA interstrand crosslink repair in mammalian cells: step by step
10.3109/10409230903501819 · 2010
PI3K/Akt signalling pathway specific inhibitors: a novel strategy to sensitize cancer cells to anti-cancer drugs
10.2174/138161210791033950 · 2010
PI3 kinase inhibitors in the clinic: an update
2012
Highlights in lung cancer
10.1183/09031936.01.00238801 · 2001
Recent advances in non-small cell lung cancer biology and clinical management
2012
Strategies for improving outcomes in NSCLC: a look to the future
10.1016/j.lungcan.2013.08.025 · 2013
Treatment of non–small-cell lung cancer with erlotinib or gefitinib
10.1056/nejmct0807960 · 2011
Gefitinib or chemotherapy for non–small-cell lung cancer with mutated EGFR
10.1056/nejmoa0909530 · 2010
Shortcomings of current therapies for non-small-cell lung cancer: unmet medical needs
10.1038/onc.2009.196 · 2009
